---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000021"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:20:41.437705+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr

## Summary
- Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.
- Decision not due to any disagreement with the company on operations, policies, or practices.
- Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.
- Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.
- Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services.

## SEC filing metadata
- accession: 0001730430-26-000021
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/0001730430-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/knsa-20260430x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000021
- JSON: https://secwatch.observer/filing/0001730430-26-000021.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000021.txt

## Key facts
- Executive change
  Eben Tessari was appointed as special advisor to the Company's Science and Research Committee at Kiniksa Pharmaceuticals International, plc.
  - Action: appointed
  - Role: special advisor to the Company's Science and Research Committee
  source text: Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/0001730430-26-000021-index.htm
- Executive change
  Eben Tessari resigned as Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc.
  - Action: resigned
  - Role: Chief Strategy Officer
  source text: On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/0001730430-26-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.